Product relaunch success is a combination of timing, investment and the science behind each drug. A
Online PR News – 27-October-2009 – – Product teams must begin their relaunch planning early to incorporate it into a strong overall lifecycle management strategy. As product teams enter Phase 2 of development for their initial launch, they are often planning their relaunch strategies for years later. Early planning is one of the key factors in making a product relaunch successful.
We analyzed the relaunch strategies outlined in this study into two categories: Line Extensions and New Market Entries. Each line extension or new market entry strategy profiled in this study includes a detailed analysis of:
* Implementation costs
* Time to implement
* Strategy outcome in terms of revenue
* Market share protection gained from implementing the tactic
Product relaunch success is a combination of timing, investment and the science behind each drug. A drug manufacturer must first identify whether a compound may be a viable relaunch candidate. Then, the manufacturer must determine the level of investment necessary to bring a relaunch product to market. The next, and perhaps most important, step is for the product team to determine when to relaunch the drug.
Companies Included in Report
Abbott Laboratories, Alexion, Allergan, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Biogen, Biovail, Center for Development and International Cooperation, Cyclacel Pharmaceuticals, Galderma, Genentech, GlaxoSmithKline, Guebet, IMB Healthcare Consultants, Institute of Clinical Research, Johnson & Johnson, KKI Technology, Merck & Co, Novartis, NPS Pharma, Onyx Pharmaceuticals, Pfizer, Pharma Green Egypt, Roemmers Centro America, Strategyx, Syncom Pharmaceutical, TEVA and UCB Pharma.
For more information, please visit :
Or email us at firstname.lastname@example.org or call +919272852585